To accomplish this goal, we experimentally derived a mutant EGFR interactome using disease-specific EGFR isoforms directly in lung cancer cells harboring EGFR mutations and hypersensitive to EGFR inhibitors using tandem affinity purification–liquid chromatography–mass spectrometry (TAP-LC-MS/MS) (Figure 1). Here, EGFR is linked to lung carcinoma.